Clinical trial
Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study…
NCT00338260 · Organon and Co, Industry · Completed
Key facts
| NCT number | NCT00338260 |
|---|---|
| Title | Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133) |
| Official title | A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy |
| Lead sponsor | Organon and Co, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart) |
| Intervention type | Drug |
| Interventions | MK0954, /Duration of Treatment : 5 Years, Comparator : atenolol /Duration of Treatment : 5 Years |
| Enrollment | 496 |
| Start date | Jun 1, 1995 |
| Primary completion | Sep 1, 2001 |
| Completion | Nov 1, 2001 |
| First posted | Jun 20, 2006 |
| Last update posted | Feb 15, 2022 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: